ADVIL LIQUI-GELS Drug Patent Profile

« Back to Dashboard

When do Advil Liqui-gels patents expire, and what generic alternatives are available?

Advil Liqui-gels is a drug marketed by Haleon Us Holdings and is included in one NDA.

The generic ingredient in ADVIL LIQUI-GELS is ibuprofen. There is one drug master file entry for this compound. Two hundred and fifty-two suppliers are listed for this compound. Additional details are available on the ibuprofen profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Advil Liqui-gels

A generic version of ADVIL LIQUI-GELS was approved as ibuprofen by CONTRACT PHARMACAL on October 15^th, 1986.

Summary for ADVIL LIQUI-GELS

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	179
Patent Applications:	3,994
What excipients (inactive ingredients) are in ADVIL LIQUI-GELS?	ADVIL LIQUI-GELS excipients list
DailyMed Link:	ADVIL LIQUI-GELS at DailyMed

Pharmacology for ADVIL LIQUI-GELS

Drug Class	Nonsteroidal Anti-inflammatory Drug
Mechanism of Action	Cyclooxygenase Inhibitors

US Patents and Regulatory Information for ADVIL LIQUI-GELS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Haleon Us Holdings	ADVIL LIQUI-GELS	ibuprofen	CAPSULE;ORAL	020402-001	Apr 20, 1995		OTC	Yes	Yes

EU/EMA Drug Approvals for ADVIL LIQUI-GELS

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Recordati Rare Diseases	Pedea	ibuprofen	EMEA/H/C/000549Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age.	Authorised	no	no	no	2004-07-28

Advil Liqui-Gels Market Dynamics, Patent Position, and Financial Trajectory

Last updated: September 24, 2026

Advil Liqui-Gels is a U.S. over-the-counter ibuprofen product marketed by Haleon plc. Each capsule generally contains 200 mg of ibuprofen in a liquid-filled gelatin dosage form. The product competes in the mature nonprescription analgesics market against Motrin IB, generic ibuprofen, acetaminophen products such as Tylenol, and naproxen products such as Aleve.

Advil Liqui-Gels has no meaningful remaining small-molecule exclusivity barrier. Its commercial position depends on brand equity, distribution, formulation convenience, shelf placement, advertising, pricing, and manufacturing scale rather than enforceable market exclusivity. Haleon does not publicly report Advil Liqui-Gels revenue as a standalone product.

What is Advil Liqui-Gels and who markets it?

Advil Liqui-Gels contains solubilized ibuprofen in a liquid-filled capsule. The dosage form is designed to differentiate the product from conventional compressed ibuprofen tablets through swallowability, presentation, and consumer perception of faster action.

Item	Publicly reported position
Brand	Advil Liqui-Gels
Active ingredient	Ibuprofen
Typical strength	200 mg per capsule
Drug class	Nonsteroidal anti-inflammatory drug
U.S. regulatory status	OTC ibuprofen product
Current brand owner and marketer	Haleon
Primary dosage form	Liquid-filled gelatin capsule
Primary indications	Temporary relief of minor aches and pains and reduction of fever
Prescription requirement	No
Biosimilar relevance	None
Standalone product revenue	Not separately disclosed by Haleon

Haleon became the independent consumer-health company created through the 2022 demerger from GSK. Its portfolio includes Advil, Voltaren, Panadol, Sensodyne, Centrum, and other consumer brands.[1]

What is the FDA regulatory status of Advil Liqui-Gels?

Advil Liqui-Gels is regulated as an OTC ibuprofen analgesic product. U.S. ibuprofen products are governed principally by the FDA OTC monograph framework and applicable labeling requirements under 21 C.F.R. Part 343.[2]

The product’s labeling must address the established risks of ibuprofen, including stomach bleeding, cardiovascular events, allergic reactions, and interactions with other medicines. FDA labeling also limits use in certain populations, including individuals with prior allergic reactions to aspirin or other NSAIDs.

The product is not a biologic and does not use an abbreviated pathway comparable to a biosimilar application. Competing manufacturers can generally market ibuprofen products by complying with the applicable OTC monograph, filing requirements, manufacturing controls, labeling rules, and establishment obligations.

Is Advil Liqui-Gels an FDA-approved prescription product?

The consumer product is sold without a prescription. The FDA has historically approved certain ibuprofen products through prescription and OTC pathways, but current Advil Liqui-Gels commercial sales are positioned within the nonprescription market.

The regulatory barrier is therefore lower than for a prescription drug requiring a new drug application, clinical development program, or therapeutic-equivalence approval. The principal regulatory risks involve formulation compliance, labeling, manufacturing quality, adverse-event reporting, and promotional claims.

What patents protect Advil Liqui-Gels?

No current patent estate is publicly associated with Advil Liqui-Gels that would block ordinary OTC ibuprofen competition in the United States. Ibuprofen itself is an old active ingredient, and foundational composition-of-matter protection expired decades ago.

The commercial formulation may have historically been covered by patents involving liquid-filled capsules, solubilized ibuprofen, excipient systems, gelatin shells, manufacturing methods, or packaging. Any such protection would need to be evaluated patent by patent by product, jurisdiction, claim scope, and expiration date. The existence of historical formulation patents would not establish current exclusivity.

Protection category	Current competitive effect
Ibuprofen composition of matter	Expired
Basic analgesic use	No practical exclusivity
Conventional tablet formulation	Generic competition
Liquid-filled capsule technology	Potentially patentable, but no known blocking exclusivity established for current U.S. sales
Brand name and trade dress	Trademark and branding protection remain relevant
Manufacturing know-how	May remain confidential and commercially useful
Packaging and advertising claims	May receive limited trademark or regulatory protection

The strongest continuing legal protections are likely trademark rights in “Advil,” product design, packaging, trade dress, and proprietary manufacturing know-how. These protections do not prevent competitors from selling ibuprofen in capsules or tablets.

When does Advil Liqui-Gels lose exclusivity?

Advil Liqui-Gels has no material remaining FDA exclusivity period comparable to the five-year new chemical entity period, three-year clinical investigation period, or pediatric exclusivity period used for prescription products.

Commercial exclusivity has already been lost to generic ibuprofen and competing branded products. The relevant question is not when a patent expires, but how much branded demand Haleon can retain after consumers and retailers have access to lower-priced alternatives.

The competitive timeline is:

Period	Market position
Early ibuprofen commercialization	Prescription and later OTC regulatory expansion
1980s onward	Broad OTC availability and rapid genericization
Post-generic market	Brand differentiation through packaging, dosing, capsules, and advertising
Current market	Mature branded-generic competition with low legal entry barriers

Are there Paragraph IV challenges to Advil Liqui-Gels?

Paragraph IV litigation is not the normal competitive mechanism for current OTC Advil Liqui-Gels sales. Paragraph IV certifications apply to abbreviated new drug applications that challenge patents listed in the FDA Orange Book. An OTC monograph product generally does not generate the same Orange Book patent-certification pathway as a prescription product protected by listed patents.

Generic ibuprofen manufacturers therefore compete primarily through OTC compliance and market entry rather than through an ANDA-based patent challenge to Advil Liqui-Gels.

No material current Paragraph IV campaign directed at Advil Liqui-Gels is publicly established in the ordinary product-level market record. A manufacturer could still face litigation over a specific formulation, trademark, packaging feature, advertising claim, or manufacturing process, but that would be a separate dispute from a conventional Orange Book patent challenge.

What is the Orange Book status of Advil Liqui-Gels?

The Orange Book is principally a reference for approved prescription and certain approved nonprescription drug applications, therapeutic equivalence, patents, and exclusivity. It is not the primary source of market exclusivity for OTC monograph ibuprofen products.

Advil Liqui-Gels does not have an Orange Book position comparable to a branded prescription medicine with multiple listed formulation and method-of-use patents. The absence of a blocking Orange Book estate is consistent with the product’s long-established OTC status and the availability of competing ibuprofen products.

What formulations are protected by Advil Liqui-Gels?

The product’s commercial differentiation comes from its liquid-filled capsule presentation. Relevant formulation attributes may include:

• Ibuprofen solubilization in a liquid vehicle.
• Gelatin capsule shell construction.
• Plasticizer and humectant systems.
• Capsule color and shape.
• Dissolution and disintegration performance.
• Fill-volume control and manufacturing tolerances.
• Packaging designed to protect the capsules from moisture and heat.

These attributes can create manufacturing complexity without creating durable legal exclusivity. A competitor can often design around a formulation patent or use a different excipient system while maintaining the same active ingredient, strength, and OTC indication.

The capsule format may carry a higher cost of goods than a standard compressed tablet. That cost can be justified when consumers pay for perceived convenience, easier swallowing, brand familiarity, or faster perceived relief.

How strong is the patent estate for Advil Liqui-Gels?

The patent estate is weak as a current market barrier and strong only in the limited sense that historical formulation and manufacturing rights may have supported product development.

Patent-strength factor	Assessment
Active ingredient protection	None remaining
Method-of-use protection	Minimal practical relevance for OTC analgesia
Formulation protection	Potentially relevant historically, but no established current blocking estate
Manufacturing protection	Possible process know-how, generally difficult to assess publicly
Trademark protection	Stronger than patent protection for brand identity
Regulatory exclusivity	No material current exclusivity period
Generic substitution risk	High
Brand-retention capability	Moderate to strong, depending on price and marketing

The product’s defensibility is commercial rather than patent-based. Haleon can protect the brand name and compete through scale, retailer relationships, advertising, product quality, and portfolio management.

Which companies challenge Advil Liqui-Gels?

The principal competitors are generic ibuprofen manufacturers and branded analgesic companies.

Direct ibuprofen competitors

• Perrigo
• CVS Health private-label suppliers
• Walmart and other private-label suppliers
• Walgreens Boots Alliance private-label suppliers
• Amazon and other retailer brands
• Motrin IB, associated with Kenvue
• Various regional and online OTC manufacturers

Substitution competitors

• Tylenol, marketed by Kenvue, containing acetaminophen
• Aleve, marketed by Bayer, containing naproxen sodium
• Bayer aspirin products
• Store-brand acetaminophen, naproxen, and aspirin
• Topical NSAID products, including Voltaren

Substitution is clinically constrained because ibuprofen, acetaminophen, and naproxen have different risk profiles, dosing intervals, and anti-inflammatory characteristics. Consumer switching is still common because many minor-pain indications overlap.

What is the competitive landscape for Advil Liqui-Gels?

The U.S. OTC analgesic market is mature, highly distributed, and promotion-sensitive. Volume growth is limited by population growth and incidence of short-term pain conditions. Value growth depends on pricing, premium dosage forms, inflation, product innovation, and mix.

Advil Liqui-Gels occupies a branded premium position relative to ordinary generic ibuprofen tablets. Its premium is vulnerable when:

• Retailers expand private-label shelf space.
• Consumers trade down during periods of financial pressure.
• Competitors match the capsule format.
• Retail promotions narrow the price gap.
• Consumers shift toward acetaminophen or naproxen.
• Retailers increase online price transparency.

The product benefits from high brand recognition, broad distribution, and established consumer usage. It faces structural pressure from low-cost alternatives because ibuprofen is widely available and easy to manufacture.

What is Advil Liqui-Gels’ financial trajectory?

Haleon does not disclose revenue, gross margin, or operating profit for Advil Liqui-Gels as a standalone SKU. Public financial reporting generally aggregates Advil within broader pain-relief, consumer-health, or regional brand categories.[1]

The likely financial trajectory is that of a mature branded OTC product:

1. Volume is constrained by category maturity and generic competition.
2. Price and mix can support nominal revenue growth.
3. Premium liquid-filled capsules can produce better revenue per unit than standard tablets.
4. Advertising and trade promotion are required to defend market share.
5. Input costs for gelatin, packaging, active ingredient, freight, and retail promotion affect margins.
6. Haleon’s scale can support manufacturing and distribution efficiency.

Revenue exposure is meaningful at the brand-family level but cannot be quantified accurately from public filings at the Advil Liqui-Gels SKU level. Investor analysis should therefore use Haleon’s pain-relief segment, regional Advil disclosures, category data, and retail scanner information rather than treating consolidated Haleon revenue as Advil revenue.

What generic launch risks exist for Advil Liqui-Gels?

Generic entry risk is already realized. The relevant risk is incremental erosion from additional private-label liquid capsules and branded alternatives.

Risk	Effect
Low-cost ibuprofen tablets	Pressures price and volume
Store-brand liquid capsules	Directly attacks the premium format
Retailer delisting	Reduces distribution and visibility
Promotional competition	Compresses net realized price
Product recalls	Can shift consumers and retailers to competitors
Manufacturing disruption	Creates out-of-stocks and lost shelf position
Adverse safety publicity	Can reduce demand across the NSAID category
E-commerce comparison pricing	Makes premium differences more visible

Haleon’s strongest response is usually brand investment, reliable supply, differentiated packaging, and portfolio coverage across tablets, capsules, children’s products, and other pain-relief formats.

What patent litigation and licensing deals affect Advil Liqui-Gels?

No major current patent litigation or licensing transaction is publicly established as a central driver of Advil Liqui-Gels’ U.S. market position. The product operates in a mature OTC category in which competition is driven more by manufacturing, branding, distribution, and retailer economics than by active patent enforcement.

Licensing arrangements may exist at the level of manufacturing, distribution, packaging, or historical brand ownership. Haleon’s public reporting does not identify a standalone Advil Liqui-Gels licensing stream or royalty burden that can be isolated from the broader Advil business.

How does Advil Liqui-Gels compare with Motrin IB and generic ibuprofen?

Factor	Advil Liqui-Gels	Motrin IB	Generic ibuprofen
Active ingredient	Ibuprofen	Ibuprofen	Ibuprofen
Typical strength	200 mg	200 mg	200 mg
Main advantage	Brand and liquid-filled capsule format	Brand recognition and distribution	Lowest price
Patent barrier	No material current barrier	No material current barrier	None
OTC availability	Yes	Yes	Yes
Price position	Premium	Premium or mid-premium	Discount
Main commercial defense	Advertising, shelf presence, capsule format	Brand and retailer presence	Price and availability

The products are pharmacologically close. The commercial difference rests on consumer preference, retailer placement, price, and perceived quality.

What geographic coverage does Advil Liqui-Gels have?

Advil is primarily a North American consumer-health brand, with the strongest commercial relevance in the United States and Canada. Product names, formulations, labeling, regulatory status, and ownership can differ by country.

Patent and trademark analysis must be conducted separately by jurisdiction. U.S. loss of exclusivity does not establish identical rights in Canada, Europe, Latin America, or Asia. OTC monograph systems also vary, creating country-specific requirements for dosage, warnings, indications, manufacturing, and advertising.

Key Takeaways

• Advil Liqui-Gels is a mature OTC ibuprofen product marketed by Haleon.
• The product’s active ingredient and core analgesic use have no meaningful remaining patent exclusivity.
• Generic ibuprofen competition is already established.
• Paragraph IV litigation and Orange Book patents are not the central market-access issues.
• The liquid-filled capsule format provides commercial differentiation but does not create a durable barrier by itself.
• Haleon does not publicly disclose Advil Liqui-Gels revenue as a standalone product.
• Financial performance depends on brand pricing, distribution, advertising, product mix, supply reliability, and private-label competition.
• The main long-term risk is premium erosion from generic and retailer-owned liquid capsules.
• Trademark, trade dress, manufacturing know-how, and consumer recognition are more important than current patent rights.

FAQs

Is Advil Liqui-Gels protected by a current U.S. patent?

No material current U.S. patent barrier is publicly established for ordinary Advil Liqui-Gels sales. Historical formulation or manufacturing patents may exist, but they do not appear to prevent generic ibuprofen competition.

Can a generic company sell an ibuprofen liquid-filled capsule?

Yes. A competing manufacturer can generally market an OTC ibuprofen capsule by complying with applicable FDA monograph, labeling, manufacturing, and quality requirements.

Does Advil Liqui-Gels have FDA exclusivity?

No material current exclusivity period comparable to prescription-drug new chemical entity or clinical-investigation exclusivity is associated with the product’s current OTC market position.

Is Advil Liqui-Gels more profitable than generic ibuprofen?

The branded product can generate higher revenue per unit and potentially higher gross profit per unit, but advertising, trade promotion, packaging, and distribution costs also are higher. Haleon does not disclose SKU-level profitability.

Who owns the Advil brand?

Haleon owns and markets Advil within its consumer-health portfolio. The brand became part of Haleon following the separation of GSK’s consumer-health business.[1]

References

1. Haleon plc. (2024). Annual report and financial statements 2023. https://www.haleon.com
2. U.S. Food and Drug Administration. (2024). Code of Federal Regulations, Title 21, Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-343
3. U.S. Food and Drug Administration. (2024). Drug products marketed under the OTC monograph system. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
5. Haleon Consumer Healthcare. (2024). Advil Liqui-Gels drug facts labeling. DailyMed. https://dailymed.nlm.nih.gov